Clinical trials: MGMT-Methylated Glioblastoma
Glioblastoma Multiforme of Brain
Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma
Newly diagnosed HLA-A2-positive MGMT-methylated glioblastoma patients will be vaccinated with a Multi peptide vaccination with Pam3Cys-GDPKHPKSF (XS15) as an immunomodulator in addition to standard postoperative radiation therapy…
- Trial name
- GLIO-XS15 (NCT04842513)
- Testing
- Multipeptide plus XS15
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University Hospital Tuebingen
Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Background: Glioblastoma (GBM) is notoriously difficult to treat, with current therapies often extending life by only a few months.
- Trial name
- NCT06419946
- Testing
- Temozolomide, Lomustine
- Where
- 20 sites in Austria, Denmark and 2 more
- Volunteers
- 200 people
- Sponsor
- Vastra Gotaland Region
Malignant Glioma of Brain
Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma
This is a Phase I study that examines the rate of dose limiting side effects in patients with malignant astrocytoma treated with combination acetazolamide (ACZ) and temozolomide (TMZ).
- Trial name
- NCT03011671
- Testing
- Acetazolamide, Temozolomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Glioblastoma
Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients
The prognosis of patients with newly diagnosed glioblastoma is dismal despite recent therapeutic improvements Using standard therapy with temozolomide (TMZ) and radiotherapy (60 Gy), the median overall survival time (mOS) is 14.6…
- Trial name
- CeTeG (NCT01149109)
- Testing
- Temozolomide and lomustine, Temozolomide
- Where
- 12 sites in Germany
- Volunteers
- 141 people
- Sponsor
- University Hospital, Bonn
Glioblastoma
A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma
An Open-Label, Multi-Center Study to Assess the Safety and Pharmacokinetics of BRCX014 Combined with Standard-of-Care Treatment in Subjects with Glioblastoma
- Trial name
- NCT03687034
- Testing
- Temozolomide, Optune
- Volunteers
- 21 people
- Sponsor
- Leaf Vertical Inc.
Glioblastoma, Gliosarcoma
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT…
- Trial name
- NCT05095376
- Testing
- Lomustine, Magnetic Resonance Imaging, Photon Beam Radiation Therapy
- Where
- 420 sites in United States, Canada
- Volunteers
- 265 people
- Sponsor
- NRG Oncology
MGMT-Methylated Glioblastoma, Glioblastoma (GBM)
G-CSF After Chemo-radiation in Patients With Glioblastoma
This research study involves the study of granulocyte colony stimulating factor (G-CSF) in patients with MGMT-methylated glioblastoma multiforme (GBM) that are undergoing standard chemoradiation.
- Conditions
- MGMT-Methylated Glioblastoma, Glioblastoma (GBM), Newly Diagnosed Glioblastoma Multiforme
- Trial name
- NCT06649851
- Testing
- Granulocyte Colony Stimulating Factor (G-CSF), Radiation Therapy + Temozolomide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma
Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients
This study will evaluate the addition of regorafenib to standard of care treatment with TMZ as adjuvant therapy, and in combination with TMZ+RT as concomitant therapy.
- Trial name
- REGOMA-2 (NCT06095375)
- Testing
- Regorafenib, Temozolomide
- Where
- 2 sites in Italy
- Volunteers
- 21 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Glioblastoma
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
This is a Phase 1, single-arm MT-125 dose escalation study followed by a Phase 2, randomized parallel design dose expansion phase, to determine the safety and tolerability of MT-125 administered 5 consecutive days a week with 2…
- Trial name
- NOVA-GBM (NCT07604285)
- Testing
- MT-125
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Myosin Therapeutics Inc.
First Progression of MGMT Promoter-methylated Glioblastoma
Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma
Romiplostim for low platelets caused by lomustine chemotherapy in patients with first recurrence (growing back) of a brain tumor, glioblastoma that is MGMT methylated.
- Trial name
- RIGOLETTO (NCT04933942)
- Testing
- Lomustine, Romiplostim
- Where
- 5 sites in Spain, Switzerland
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioblastoma, Brain Cancer
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) for the treatment of newly…
- Conditions
- Glioblastoma, Brain Cancer, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain
- Trial name
- NCT06991101
- Testing
- Ruxolitinib, Temozolomide, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 190 people
- Sponsor
- Baptist Health South Florida
Brain Neoplasms
An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
The purpose of this study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change). Patients will receive temozolomide plus radiation therapy.
- Trial name
- CheckMate548 (NCT02667587)
- Testing
- Nivolumab, Temozolomide, Radiotherapy
- Where
- 123 sites in United States, Australia and 17 more
- Volunteers
- 716 people
- Sponsor
- Bristol-Myers Squibb
Glioblastoma
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed…
- Trial name
- GBM AGILE (NCT03970447)
- Testing
- Temozolomide, Lomustine, Regorafenib
- Where
- 63 sites in United States, Australia and 4 more
- Volunteers
- 2,250 people
- Sponsor
- Global Coalition for Adaptive Research
Glioblastoma
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
CENTRIC is a Phase 3 clinical trial assessing efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment versus standard treatment alone in newly diagnosed glioblastoma…
- Trial name
- CENTRIC (NCT00689221)
- Testing
- Cilengitide, Temozolomide, Radiotherapy
- Where
- 2 sites in United States, Germany
- Volunteers
- 545 people
- Sponsor
- EMD Serono
High Grade Glioma, MGMT-Unmethylated Glioblastoma
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients.
- Conditions
- High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
- Trial name
- NCT06504381
- Testing
- DB107-RRV, DB107-FC, Radiation Therapy (RT)
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Francisco
MGMT-Methylated Glioblastoma
6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM)
The primary objective of this trial is to evaluate overall survival of patients with O[6]-methylguanine-DNA methyltransferase (MGMT) methylated glioblastoma treated with or without six months of adjuvant TMZ after standard…
- Trial name
- NCT04926168
- Testing
- Delay of TMZ, Standard of Care (SOC) Adjuvant TMZ (no intervention
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy…
- Trial name
- NCT05432804
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Selinexor
- Where
- 39 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Cancer Institute (NCI)
Glioma, Glioblastoma (GBM)
STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation
To compare the efficacy and safety of Lenvatinib combined with the standard Stupp regimen versus the standard Stupp regimen alone in the treatment of newly diagnosed glioblastoma with MGMT promoter methylation positive.
- Conditions
- Glioma, Glioblastoma (GBM), MGMT-Methylated Glioblastoma
- Trial name
- NCT07754734
- Testing
- Lenvatinib, TMZ (Temozolomide), radiotherapy
- Volunteers
- 138 people
- Sponsor
- Dongguan People's Hospital
Grade IV Astrocytoma, Glioblastoma
Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma
O6-méthylguanine méthyltransférase (MGMT) is the main repair gene after DNA lesion induced by Temozolomide in combination with radiation therapy of Glioblastoma (GBM) in Stupp.R et al published regimen.
- Trial name
- FOLAGLI (NCT01700569)
- Testing
- Temozolomide, folinic acid at pharmacological dose is the escalated drug, High voltage radiation therapy (linear accelerator)
- Where
- 4 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut Cancerologie de l'Ouest
Recurrent Glioblastoma Multiforme
Procarbazine and Lomustine in Recurrent Glioblastoma
The combination therapy of temozolomide and radiation has been established as the standard therapy for the initial treatment of glioblastoma.
- Trial name
- NCT01737346
- Testing
- lomustine and procarbazine
- Where
- South Korea
- Volunteers
- 52 people
- Sponsor
- Incheon St.Mary's Hospital